BR9605968A - Nova modificaçao de cristal de cdch um processo para a sua preparaçao e formulaçoes farmaceuticas compreendendo esta modificaçao - Google Patents

Nova modificaçao de cristal de cdch um processo para a sua preparaçao e formulaçoes farmaceuticas compreendendo esta modificaçao

Info

Publication number
BR9605968A
BR9605968A BR9605968A BR9605968A BR9605968A BR 9605968 A BR9605968 A BR 9605968A BR 9605968 A BR9605968 A BR 9605968A BR 9605968 A BR9605968 A BR 9605968A BR 9605968 A BR9605968 A BR 9605968A
Authority
BR
Brazil
Prior art keywords
modification
cdch
preparation
new
pharmaceutical formulations
Prior art date
Application number
BR9605968A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick Bosche
Alfons Grunenberg
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9605968(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9605968A publication Critical patent/BR9605968A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9605968A 1995-12-12 1996-12-11 Nova modificaçao de cristal de cdch um processo para a sua preparaçao e formulaçoes farmaceuticas compreendendo esta modificaçao BR9605968A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
BR9605968A true BR9605968A (pt) 1998-08-18

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9605968A BR9605968A (pt) 1995-12-12 1996-12-11 Nova modificaçao de cristal de cdch um processo para a sua preparaçao e formulaçoes farmaceuticas compreendendo esta modificaçao

Country Status (42)

Country Link
US (1) US5849752A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0780390B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4104687B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100525146B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1061348C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR005009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE221531T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU708006B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62258B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9605968A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2192418C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4480105A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU22774A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ288657B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE19546249A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0780390T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03474B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2179910T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP960558B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226521B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID22625A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL119795A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN185805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA24342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY117492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300109I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306725B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ299905A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL184885B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT780390E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO119782B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2162468C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA96170492B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG47201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0780390T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282805B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV1996000109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199600970A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW411340B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA35638C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU49485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9610405B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731693B2 (en) * 1997-09-25 2001-04-05 Bayer Intellectual Property Gmbh Drug formulation having controlled release of active compound
DE19751948A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
HK1042245B (zh) * 1998-11-10 2005-03-11 Bayer Intellectual Property Gmbh 莫西沙星药物制剂
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
WO2004039804A1 (en) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Amorphous moxifloxacin hydrochloride
ATE439840T1 (de) 2003-04-09 2009-09-15 Reddys Lab Ltd Dr Kristalline form iii von wasserfreiem moxifloxacin-hydrochlorid und ein verfahren zu seiner herstellung
US20060264635A1 (en) * 2003-08-05 2006-11-23 Chava Satyanarayana Process for the preparation of moxifloxacin hydrochloride
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
ES2319125T3 (es) * 2003-11-20 2009-05-04 Chemi S.P.A. Polimorfos del clorhidrato del acido 1-ciclopropil-7-((s,s)-2,8-diazadiciclo(4.3.0)-non-8-il)-6-fluoro-1,4-dihidro-8-metoxi-4-oxo-3-quinolina carboxilico y metodos para la preparacion de los mismos.
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
SI2032521T1 (sl) 2006-06-27 2010-02-26 Sandoz Ag Nov postopek za pripravo soli
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
EP2474547A3 (en) * 2006-11-13 2012-07-25 Cipla Limited Process for the Synthesis of Moxifloxacin Hydrochloride
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
BRPI0823092A2 (pt) * 2008-10-09 2015-09-29 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi método de granulação úmida de moxifloxacin anídrico ou seus sais
EP2342204A1 (en) * 2008-11-06 2011-07-13 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
EA028676B1 (ru) 2008-12-08 2017-12-29 Рациофарм Гмбх Спрессованный моксифлоксацин
NZ610978A (en) 2009-05-15 2014-11-28 Redx Pharma Ltd Redox drug derivatives
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
WO2014087292A1 (en) 2012-12-04 2014-06-12 Mankind Research Centre An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
MX388561B (es) 2013-03-15 2025-03-11 Melinta Subsidiary Corp Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
AU618235B2 (en) * 1986-03-31 1991-12-19 Sankyo Company Limited Quinoline-3-carboxylic acid derivatives, their preparation and use
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-10 1993-07-21 Bayer Ag
ES2167329T3 (es) * 1992-01-31 2002-05-16 Chugai Pharmaceutical Co Ltd Cristal de hidrato de derivado de acido quinolonacarboxilico.
DE4234078A1 (de) 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
DE69504392T2 (de) * 1994-04-07 1999-02-11 Pfizer Inc., New York, N.Y. Verwendung von Trovafloxacin oder dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung von H.Pylori Infektionen

Also Published As

Publication number Publication date
JPH09169757A (ja) 1997-06-30
MX9606325A (es) 1997-10-31
CZ364696A3 (en) 1997-07-16
HUP9603428A3 (en) 1997-10-28
CA2192418A1 (en) 1997-06-13
HUP9603428A2 (en) 1997-08-28
KR970042550A (ko) 1997-07-24
RU2162468C2 (ru) 2001-01-27
NO965298L (no) 1997-06-13
KR100525146B1 (ko) 2006-01-27
SI0780390T1 (en) 2002-10-31
NO306725B1 (no) 1999-12-13
HU9603428D0 (en) 1997-01-28
PL317415A1 (en) 1997-06-23
HU226521B1 (en) 2009-03-30
EP0780390B1 (de) 2002-07-31
SA96170492B1 (ar) 2006-05-23
CZ288657B6 (cs) 2001-08-15
SK282805B6 (sk) 2002-12-03
PL184885B1 (pl) 2003-01-31
AU7421696A (en) 1997-06-19
CN1061348C (zh) 2001-01-31
CN1160052A (zh) 1997-09-24
DK0780390T3 (da) 2002-11-11
TW411340B (en) 2000-11-11
UA35638C2 (uk) 2001-04-16
AR005009A1 (es) 1999-04-07
US5849752A (en) 1998-12-15
EP0780390A1 (de) 1997-06-25
RO119782B1 (ro) 2005-03-30
ZA9610405B (en) 1997-06-23
JP4104687B2 (ja) 2008-06-18
CU22774A3 (es) 2002-07-24
SV1996000109A (es) 1997-10-23
NZ299905A (en) 1998-09-24
YU49485B (sh) 2006-08-17
IL119795A0 (en) 1997-03-18
NO965298D0 (no) 1996-12-11
IL119795A (en) 1998-12-27
EE9600201A (et) 1997-06-16
CA2192418C (en) 2001-06-12
TR199600970A2 (tr) 1997-06-21
PT780390E (pt) 2002-11-29
BG101043A (en) 1998-04-30
ID22625A (id) 1999-12-02
CO4480105A1 (es) 1997-07-09
NL300109I1 (nl) 2003-02-03
EE03474B1 (et) 2001-08-15
AU708006B2 (en) 1999-07-29
DE59609501D1 (de) 2002-09-05
ATE221531T1 (de) 2002-08-15
MY117492A (en) 2004-07-31
IN185805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-05-05
ES2179910T3 (es) 2003-02-01
MA24342A1 (fr) 1998-07-01
DE19546249A1 (de) 1997-06-19
BG62258B1 (bg) 1999-06-30
SG47201A1 (en) 1998-03-20
SK159196A3 (en) 1997-10-08
YU65096A (sh) 1998-12-23
HRP960558B1 (en) 2002-04-30
HRP960558A2 (en) 1998-02-28

Similar Documents

Publication Publication Date Title
BR9605968A (pt) Nova modificaçao de cristal de cdch um processo para a sua preparaçao e formulaçoes farmaceuticas compreendendo esta modificaçao
BR9601028A (pt) Compostos processo para sua preparação processo para a produção de preparações farmacêuticas preparação farmacêutica medicamento e uso
BR9504509A (pt) Composto processo para sua preparaçao e formulaçao farmaceûtica
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR9602150A (pt) Compostos processo para sua preparação processo para a produção de uma formulação farmacêutica formulação farmacêutica e uso
BR9607200A (pt) Biomaterial para uso na cirurgia e processo para a sua produção
BR9709885A (pt) Dispositivo médico processo para sua manufatura e uso de um copolímero de bloco de estireno
BR9601275A (pt) Compostos processo para sua preparação medicamentos preparação farmacêutica processo para sua produção e uso
BR9204361A (pt) Composto e processo para sua preparacao formulacao farmaceutica e intermediario
BR9408219A (pt) Comprimidos de paroxetina e um processo para a sua preparação
PT1010423E (pt) Preparacao farmaceutica oral que contem um derivado benzimidazolico com accao anti-ulcerosa e processo para a sua producao
BR9605354A (pt) Composto composição farmacêutica processo para a produção do composto e uso
PT854880E (pt) Novos derivados de 5-o-desosaminil 6-o-metil eritronolido a metodo para a sua preparacao e a sua utilizacao na preparacao de produtos biologicamente activos
BR9201017A (pt) Composicao de amaciamento de tecido e processo para sua preparacao
BR9609327A (pt) Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos
BR9206950A (pt) Composição farmacêutica e processo para sua preparação
BR9602983A (pt) Gel e processo para sua preparação
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
BR9600145A (pt) Processo para obtenção de uma preparação de flavana-lignana composto de flavano-lignana medicamento e processo para sua preparação
PT854879E (pt) Novos derivados de 5-o-desosaminil-6-o-metil-eritronolida a, processo para a sua preparacao e sua aplicacao a preparacao de produtos biologicamente activos
PT783310E (pt) Novos medicamentos hormonais e sua utilizacao para a correccao de carencias estrogenicas
BR9203508A (pt) Composto,processo para a sua preparacao,medicamento,uso em um composto e metodo de tratar ou evitar doencas inflamatorias
BR9600778A (pt) Benzenossulfoniluréia e - tiouréla substituida processo para sua preparação seu uso e medicamento

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER HEALTHCARE AG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B25D Requested change of name of applicant approved

Free format text: TRANSFERIDO DE: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]